← Back to headlines
Dyne Therapeutics Stock Rises as Duchenne Therapy Trial Begins
Dyne Therapeutics' stock saw a significant increase following the commencement of a late-stage clinical trial for its Duchenne muscular dystrophy therapy.
20 May, 17:08 — 20 May, 17:08
Sources
Showing 1 of 1 sources
Related Stories
'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video
just now
Handwriting Analysis May Reveal Early Signs of Alzheimer's Disease
31m ago
Copenhagen Experiences Strongest Earthquake Since 2012
32m ago
Italian Divers Possibly Trapped by Venturi Effect in Cave
38m ago